JP3864431B2 - A stable solution containing licorice extract - Google Patents

A stable solution containing licorice extract Download PDF

Info

Publication number
JP3864431B2
JP3864431B2 JP16788195A JP16788195A JP3864431B2 JP 3864431 B2 JP3864431 B2 JP 3864431B2 JP 16788195 A JP16788195 A JP 16788195A JP 16788195 A JP16788195 A JP 16788195A JP 3864431 B2 JP3864431 B2 JP 3864431B2
Authority
JP
Japan
Prior art keywords
licorice
extract
polyoxyethylene
dissolved
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP16788195A
Other languages
Japanese (ja)
Other versions
JPH08333268A (en
Inventor
勝博 深堀
洋明 高橋
英知 櫻井
重男 木村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Original Assignee
Zeria Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharmaceutical Co Ltd filed Critical Zeria Pharmaceutical Co Ltd
Priority to JP16788195A priority Critical patent/JP3864431B2/en
Publication of JPH08333268A publication Critical patent/JPH08333268A/en
Application granted granted Critical
Publication of JP3864431B2 publication Critical patent/JP3864431B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【0001】
【産業上の利用分野】
本発明はカンゾウの抽出物を配合する液剤に関し、詳しくは長期間保存した場合に沈澱、浮遊物生成などの外観劣化が生じない、安定な液剤に関するものである。
【0002】
【従来の技術】
従来、生薬の抽出物を配合した液剤は、長期間の保存により沈澱、懸濁又は浮遊物生成などの外観劣化が生じやすく、これを防止するために種々検討がなされている。
生薬の抽出物に由来する外観劣化を抑える方法としては、以下の方法が知られている。すなわち、生薬抽出物中の不溶性異物の原因成分を、▲1▼加熱又はpH調整によって析出させ濾過して除去する方法、▲2▼多量の界面活性剤を使用して可溶化する方法があげられる。また、▲3▼特開昭61−268627号公報には、ポリオキシエチレン硬化ヒマシ油誘導体及びポリビニルピロリドンを配合してpHを3.0〜4.5に調整することにより、外観劣化を防止する方法が、▲4▼特開昭61−210038号公報には、オウレンの抽出物とカンゾウの抽出物にポリビニルピロリドンを添加することにより、オウレン中のベルベリンとカンゾウ中のグリチルリチン酸とから酸・塩基反応によって生じるコンプレックスの生成を抑える方法が開示されている。
【0003】
【発明が解決しようとする課題】
しかしながら、▲1▼の方法では、必要な有効成分の除去、加熱による成分の分解、pH調整に伴う成分の安定性の低下などが考えられるため、調製工程を複雑なものとしている。また、▲2▼の方法では、界面活性剤が多量必要であるため、界面活性剤の生体に及ぼす影響を考えると、安全性の面からも好ましい方法とはいい難い。▲3▼の方法では、ポリオキシエチレン硬化ヒマシ油が低いpHで分解しやすいため、pHの調整が必須であり、その結果防腐効力の低下や嗜好の低下が生じる。さらに、▲4▼の方法は、オウレンとカンゾウを配合する液剤のみに適用されるものである。
そこで、より簡便で有効成分に影響を及ぼさず外観劣化を防止し、また添加した成分が安全性に影響せず、かつ調製工程が簡便な方法の開発が要望されていた。
【0004】
【課題を解決するための手段】
本発明者らは、前記課題を解決するために鋭意検討を重ねた結果、カンゾウの抽出物を配合した液剤にポリオキシエチレン・ポリオキシプロピレングリコール、あるいはポリビニルピロリドンとポリオキシエチレン・ポリオキシプロピレングリコールを配合することによって、長時間保存した場合に沈殿、懸濁、浮遊物生成などの外観劣化を防止できることを見出し、本発明を完成した。
【0005】
すなわち、本発明はカンゾウの抽出物に、ポリオキシエチレン・ポリオキシプロピレングリコールあるいはポリビニルピロリドンとポリオキシエチレン・ポリオキシプロピレングリコールを配合することによって、長時間保存した場合に沈殿、懸濁、浮遊物生成などの外観劣化が生じない、安定な液剤に関するものである。
【0006】
本発明において用いられるカンゾウの抽出物は、どのような方法で抽出されたものでもよく、例えば日本薬局方に示された方法により製した、チンキ、流エキス、軟エキス、乾燥エキスなどを使用することができる。カンゾウの抽出物の配合量は、本発明の目的を達成するのに必要な量であればよく、特に原生薬換算量として0.01〜5重量%となるように配合することが好ましい。
また、原生薬換算量とは、カンゾウの成分量を、その成分量を抽出するのに必要な原生薬の量で表したものである。
【0007】
本発明において用いられるポリビニルピロリドンとしては、特に分子量により制限されず、例えば市販のコリドン25(ビーエーエスエフジャパン社製:分子量約2.5万)、プラスドンK−25(五協産業社製:分子量約2.5万)、コリドン30(ビーエーエスエフジャパン社製:分子量約4万)、プラスドンK−29/32(五協産業社製:分子量約4万)、コリドン90(ビーエーエスエフジャパン社製:分子量約120万)、プラスドンK−90(五協産業社製:分子量約120万)などを用いることができる。配合量は、本発明の目的を達成するのに必要な量であればよく、特に0.01〜5重量%となるように配合することが好ましく、さらには0.02〜2重量%が好ましい。
【0008】
本発明において用いられるポリオキシエチレン・ポリオキシプロピレングリコールとしては、市販されているものでよく、例えばPEP101(フロイント産業社製)、プルロニックF68(旭電化工業社製)、ユニルーブ(日本油脂社製)などが挙げられる。配合量は、本発明の目的を達成するのに必要な量であればよいが、特に0.01〜2重量%となるように配合することが好ましく、さらには、0.02〜1重量%が好ましい。
【0009】
本発明の液剤は、例えばカンゾウの抽出物を水に溶解し、これにポリオキシエチレン・ポリオキシプロピレングリコール、あるいはポリビニルピロリドンとポリオキシエチレン・ポリオキシプロピレングリコールを配合し、必要に応じてpHを調整して製することができる。
【0010】
本発明の液剤には、必要に応じてニンジン、イカリソウ、オウギ、キョウニン、ゴオウ、オウセイ、ゴミシ、オンジ、ガラナ、クコシ、ケイヒ、ジオウ、トウキ、タイソウなどの生薬の抽出物、リン酸ジヒドロコデイン、塩酸メチルエフェドリン、グアヤコールスルホン酸カリウムなどの鎮咳去痰薬、アセトアミノフェンなどの解熱鎮痛薬、マレイン酸クロルフェニラミンなどの抗ヒスタミン薬、硝酸チアミン、リン酸リボフラビンナトリウム、塩酸ピリドキシン、シアノコバラミンやニコチン酸アミドなどのビタミン類をはじめとする生理活性成分を配合することができる。さらに、エタノール、プロピレングリコール、ポリビニルアルコールなどのアルコール類、ポリオキシエチレンステアレート、ポリオキシエチレンソルビタンモノオレエートなどの界面活性剤、カルボキシビニルポリマー、カルボキシメチルセルロース塩、アルギン酸塩、グリセリン、ヒドロキシプロピルセルロース、マクロゴールなどの増粘剤、ブドウ糖、果糖、還元麦芽糖、サッカリン、ソルビトール、単シロップ、白糖、ハチミツ、マンニトール、水飴などの甘味剤、リン酸塩、クエン酸塩、酢酸塩、グルタミン酸塩、マレイン酸塩、フマル酸塩、酒石酸塩、炭酸塩、乳酸塩、リンゴ酸塩、コハク酸塩などの酸味剤、安息香酸塩、パラオキシ安息香酸アルキルエステル類、ソルビン酸塩、デヒドロ酢酸塩などの防腐剤、塩酸や水酸化ナトリウムなどのpH調整剤、香料などの添加剤を加えることができる。
かくして得られる液剤は常法によって加熱滅菌することにより経口投与可能な内服液剤とすることができる。
【0011】
本発明は、カンゾウの抽出物に、ポリオキシエチレン・ポリオキシプロピレングリコール、あるいはポリビニルピロリドンとポリオキシエチレン・ポリオキシプロピレングリコールを配合することにより達成され、その結果、外観に優れ、特に長期間保存した場合に沈殿、懸濁、浮遊物生成などの外観劣化が起こらない液剤を提供することができる。
【0012】
【実施例】
以下に実施例を挙げて本発明を具体的に説明するが、本発明はこれらに限定されるものではない。
【0014】
実施例
カンゾウ軟エキス200mg(カンゾウ800mgに相当)を精製水に溶解し、これにプルロニックF68 100mg、リン酸リボフラビンナトリウム5mg、塩酸ピリドキシン30mg、果糖ブドウ糖液糖10g、クエン酸150mgおよびパラオキシ安息香酸エチル10mgを加えて溶解した。この水溶液をpH4.5に調整後、精製水を加え全量を100mLとし、濾紙濾過後、ガラス瓶に充填し、キャップを施して加熱滅菌し液剤とした。
【0015】
実施例
カンゾウエキス400mg(カンゾウ2000mgに相当)、ニンジンエキス50mg(ニンジン350mgに相当)およびゴオウチンキ1g(ゴオウ10mgに相当)を精製水に溶解し、これにコリドン30 300mg、プルロニックF68 300mg、アミノエチルスルホン酸1000mg、リン酸リボフラビンナトリウム5mg、塩酸ピリドキシン30mg、白糖10g、クエン酸200mgおよびパラオキシ安息香酸ブチル10mgを加え溶解した。この水溶液をpH5.0に調整後、精製水を加え全量を100mLとし、濾紙濾過後、ガラス瓶に充填し、キャップを施して加熱滅菌し液剤とした。
【0016】
実施例
カンゾウ流エキス5000mg(カンゾウ5000mgに相当)を精製水に溶解し、これにコリドン30 500mg、プルロニックF68 500mg、アセトアミノフェン500mg、d−マレイン酸クロルフェニラミン2mg、リン酸ジヒドロコデイン10mg、安息香酸ナトリウムカフェイン150mg、リン酸リボフラビンナトリウム4mg、塩酸ピリドキシン25mg、白糖15g、クエン酸150mg、およびパラオキシ安息香酸ブチル12mgを加えて溶解した。この水溶液をpH5.0に調整後、精製水を加え全量を100mLとし、濾紙濾過後、ガラス瓶に充填し、キャップを施して加熱滅菌し液剤とした。
【0017】
比較例1
カンゾウ乾燥エキス50mg(カンゾウ200mgに相当)を精製水に溶解し、これにリン酸ジヒドロコデイン60mg、塩酸メチルエフェドリン160mg、グアヤコールスルホン酸カリウム200mg、白糖20g、クエン酸200mgおよび安息香酸ナトリウム50mgを加え溶解した。この水溶液をpH4.0に調整後、精製水を加えて全量を100mlとし、濾紙濾過後、ガラス瓶に充填し、キャップを施して加熱滅菌し液剤とした。
【0018】
比較例2
カンゾウ軟エキス200mg(カンゾウ800mgに相当)を精製水に溶解し、これにリン酸リボフラビンナトリウム5mg、塩酸ピリドキシン30mg、果糖ブドウ糖液糖10g、クエン酸150mgおよびパラオキシ安息香酸エチル10mgを加え溶解した。この水溶液をpH4.5に調整後、精製水を加え全量を100mlとし、濾紙濾過後、ガラス瓶に充填し、キャップを施して加熱滅菌し液剤とした。
【0019】
比較例3
カンゾウエキス400mg(カンゾウ2000mgに相当)、ニンジンエキス50mg(ニンジン350mgに相当)およびゴオウチンキ1g(ゴオウ10mgに相当)を精製水に溶解し、これにアミノエチルスルホン酸1000mg、リン酸リボフラビンナトリウム5mg、塩酸ピリドキシン30mg、白糖10g、クエン酸200mgおよびパラオキシ安息香酸ブチル10mgを加え溶解した。この水溶液をpH5.0に調整後、精製水を加え全量を100mlとし、濾紙濾過後、ガラス瓶に充填し、キャップを施して加熱滅菌し液剤とした。
【0020】
比較例4
カンゾウ流エキス5000mg(カンゾウ5000mgに相当)を精製水に溶解し、これにアセトアミノフェン500mg、d−マレイン酸クロルフェニラミン2mg、リン酸ジヒドロコデイン10mg、安息香酸ナトリウムカフェイン150mg、リン酸リボフラビンナトリウム4mg、塩酸ピリドキシン25mg、白糖15g、クエン酸150mgおよびパラオキシ安息香酸ブチル12mgを加え溶解した。この水溶液をpH5.0に調整後、精製水を加え全量を100mlとし、濾紙濾過後、ガラス瓶に充填し、キャップを施して加熱滅菌し液剤とした。
【0021】
<比較試験>
実施例1〜4で得た本発明の液剤と、比較例1〜4で得た液剤とを40℃−相対湿度75%および25℃の条件下に保存し、内容液の外観を観察した。外観劣化の程度は、表1に示す外観観察基準により判定した。
【0022】
【表1】

Figure 0003864431
【0023】
試験の結果を表2および表3に示す。
【0024】
【表2】
Figure 0003864431
【0025】
【表3】
Figure 0003864431
【0026】
表2および表3から明らかなように、比較例の液剤では外観劣化が顕著に認められたのに対して、本発明の液剤は外観劣化がほとんど認められず、外観安定性に優れていることが証明された。
【0027】
【発明の効果】
本発明の液剤は、外観安定性に優れ、長期間保存した場合に沈澱、懸濁、浮遊物生成などの外観劣化がほとんど起こらないため、極めて有用である。[0001]
[Industrial application fields]
The present invention relates to a liquid preparation containing an extract of licorice, and more particularly to a stable liquid preparation that does not cause appearance deterioration such as precipitation and formation of floating substances when stored for a long period of time.
[0002]
[Prior art]
Conventionally, liquid preparations containing extracts of herbal medicines are likely to be deteriorated in appearance such as precipitation, suspension, or floatation by long-term storage, and various studies have been made to prevent this.
The following methods are known as methods for suppressing the appearance deterioration derived from the herbal extract. That is, there are (1) a method in which causative components of insoluble foreign substances in herbal extracts are deposited by heating or pH adjustment and filtered to remove, and (2) a method in which solubilization is performed using a large amount of surfactant. . (3) In Japanese Patent Application Laid-Open No. 61-268627, polyoxyethylene hydrogenated castor oil derivative and polyvinylpyrrolidone are blended to adjust the pH to 3.0 to 4.5, thereby preventing deterioration of the appearance. (4) Japanese Patent Application Laid-Open No. 61-210038 discloses a method in which polyvinylpyrrolidone is added to an extract of oren and an extract of licorice so that berberine in oleen and glycyrrhizic acid in licorice A method for suppressing the formation of a complex caused by the reaction is disclosed.
[0003]
[Problems to be solved by the invention]
However, in the method (1), since the necessary active ingredients are removed, the ingredients are decomposed by heating, and the stability of the ingredients is decreased due to pH adjustment, the preparation process is complicated. In addition, since the method (2) requires a large amount of surfactant, considering the influence of the surfactant on the living body, it is difficult to say that the method is preferable from the viewpoint of safety. In the method (3), since the polyoxyethylene hydrogenated castor oil is easily decomposed at a low pH, it is essential to adjust the pH. As a result, the antiseptic effect and the taste are lowered. Furthermore, the method of (4) is applied only to the liquid agent which mixes aurene and licorice.
Therefore, there has been a demand for the development of a method that is simpler and prevents appearance deterioration without affecting the active ingredient, and that the added component does not affect safety and that the preparation process is simple.
[0004]
[Means for Solving the Problems]
As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that a solution containing a liquorice extract is mixed with polyoxyethylene / polyoxypropylene glycol, or polyvinylpyrrolidone and polyoxyethylene / polyoxypropylene glycol. It was found that, by blending, appearance deterioration such as precipitation, suspension, and suspended matter formation can be prevented when stored for a long time, and the present invention has been completed.
[0005]
That is, the present invention is a mixture of licorice extract with polyoxyethylene / polyoxypropylene glycol or polyvinyl pyrrolidone and polyoxyethylene / polyoxypropylene glycol, so that it is precipitated, suspended, or suspended when stored for a long time. The present invention relates to a stable liquid agent that does not cause appearance deterioration such as generation.
[0006]
The licorice extract used in the present invention may be extracted by any method, for example, a tincture, a flow extract, a soft extract, a dry extract, etc. produced by the method shown in the Japanese Pharmacopoeia. be able to. The amount of the extract of licorice may be an amount necessary to achieve the object of the present invention, and it is particularly preferable that the amount of the licorice extract is 0.01 to 5% by weight as the amount of the drug substance.
In addition, the amount equivalent to the active ingredient is the amount of the ingredient of licorice expressed by the amount of the active ingredient necessary for extracting the amount of the ingredient.
[0007]
The polyvinyl pyrrolidone used in the present invention is not particularly limited by the molecular weight. For example, commercially available Kollidon 25 (manufactured by BASF Japan Ltd .: molecular weight of about 25,000), Plasdon K-25 (manufactured by Gokyo Sangyo Co., Ltd .: molecular weight of about 25,000), Kollidon 30 (manufactured by BSF Japan, Inc .: molecular weight of about 40,000), Plusdon K-29 / 32 (manufactured by Gokyo Sangyo Co., Ltd .: molecular weight of about 40,000), Kollidon 90 (manufactured by BASF Japan, Inc .: molecular weight) About 1.2 million), plusdon K-90 (manufactured by Gokyo Sangyo Co., Ltd .: molecular weight of about 1.2 million) and the like can be used. The blending amount may be an amount necessary to achieve the object of the present invention, and is preferably blended so as to be 0.01 to 5% by weight, more preferably 0.02 to 2% by weight. .
[0008]
The polyoxyethylene / polyoxypropylene glycol used in the present invention may be commercially available, for example, PEP101 (manufactured by Freund Corporation), Pluronic F68 (manufactured by Asahi Denka Kogyo Co., Ltd.), Unilube (manufactured by NOF Corporation). Etc. The blending amount may be an amount necessary to achieve the object of the present invention, but it is particularly preferable that the blending amount is 0.01 to 2% by weight, and further 0.02 to 1% by weight. Is preferred.
[0009]
The liquid preparation of the present invention, for example, is obtained by dissolving an extract of licorice in water and blending it with polyoxyethylene / polyoxypropylene glycol or polyvinylpyrrolidone and polyoxyethylene / polyoxypropylene glycol. It can be made by adjusting.
[0010]
The liquid preparation of the present invention may contain, as necessary, extracts of herbal medicines such as carrots, licorice, ogi, kyonin, goose, seisei, trash, onji, guarana, kokushi, keihi, jiou, toki, and isotope, dihydrocodeine phosphate, and hydrochloric acid. Antitussive expectorants such as methylephedrine and potassium guaiacol sulfonate, antipyretic analgesics such as acetaminophen, antihistamines such as chlorpheniramine maleate, thiamine nitrate, sodium riboflavin phosphate, pyridoxine hydrochloride, cyanocobalamin and nicotinamide Physiologically active ingredients including various vitamins can be blended. Furthermore, alcohols such as ethanol, propylene glycol, polyvinyl alcohol, surfactants such as polyoxyethylene stearate, polyoxyethylene sorbitan monooleate, carboxyvinyl polymer, carboxymethylcellulose salt, alginate, glycerin, hydroxypropylcellulose, Thickeners such as macrogol, glucose, fructose, reduced maltose, saccharin, sorbitol, simple syrup, sweeteners such as sucrose, honey, mannitol, varicella, phosphate, citrate, acetate, glutamate, maleic acid Salt, fumarate, tartrate, carbonate, lactate, malate, succinate and other acidulants, benzoates, paraoxybenzoic acid alkyl esters, sorbates, dehydroacetates and other preservatives, Hydrochloric acid or hydroxide pH adjusting agents such as helium, may be added additives such as perfumes.
The solution thus obtained can be made into an oral solution which can be administered orally by heat sterilization by a conventional method.
[0011]
The present invention is achieved by blending licorice extract with polyoxyethylene / polyoxypropylene glycol, or polyvinylpyrrolidone and polyoxyethylene / polyoxypropylene glycol. In this case, it is possible to provide a liquid agent that does not cause appearance deterioration such as precipitation, suspension, and suspended matter generation.
[0012]
【Example】
EXAMPLES The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples.
[0014]
Example 1
200 mg of licorice soft extract (equivalent to 800 mg of licorice) was dissolved in purified water, and 100 mg of Pluronic F68, 5 mg of riboflavin sodium phosphate, 30 mg of pyridoxine hydrochloride, 10 g of fructose glucose liquid sugar, 150 mg of citric acid and 10 mg of paraoxybenzoate were added. And dissolved. After adjusting this aqueous solution to pH 4.5, purified water was added to make up a total volume of 100 mL, filtered through filter paper, filled into a glass bottle, capped and sterilized by heating to obtain a solution.
[0015]
Example 2
Licorice extract 400 mg (corresponding to 2000 mg of licorice), carrot extract 50 mg (corresponding to 350 mg of carrot) and 1 g of goldfish tincture (corresponding to 10 mg of carrot) were dissolved in purified water, and this was dissolved in Kollidon 30 300 mg, Pluronic F68 300 mg, aminoethylsulfonic acid 1000 mg 5 mg of riboflavin sodium phosphate, 30 mg of pyridoxine hydrochloride, 10 g of sucrose, 200 mg of citric acid and 10 mg of butyl paraoxybenzoate were dissolved. The aqueous solution was adjusted to pH 5.0, purified water was added to make the total volume 100 mL, filtered through filter paper, filled into a glass bottle, capped and sterilized by heating to obtain a solution.
[0016]
Example 3
Licorice extract 5000 mg (corresponding to licorice 5000 mg) was dissolved in purified water, and Kollidon 30 500 mg, Pluronic F68 500 mg, Acetaminophen 500 mg, d-chlorpheniramine maleate 2 mg, dihydrocodeine phosphate 10 mg, sodium benzoate cafe In 150 mg, riboflavin sodium phosphate 4 mg, pyridoxine hydrochloride 25 mg, sucrose 15 g, citric acid 150 mg, and butyl paraoxybenzoate 12 mg were added and dissolved. The aqueous solution was adjusted to pH 5.0, purified water was added to make the total volume 100 mL, filtered through filter paper, filled into a glass bottle, capped and sterilized by heating to obtain a solution.
[0017]
Comparative Example 1
50 mg of dried licorice extract (corresponding to 200 mg of licorice) was dissolved in purified water, and 60 mg of dihydrocodeine phosphate, 160 mg of methylephedrine hydrochloride, 200 mg of potassium guaiacol sulfonate, 20 g of sucrose, 200 mg of citric acid and 50 mg of sodium benzoate were dissolved therein. . After adjusting this aqueous solution to pH 4.0, purified water was added to make the total volume 100 ml, filtered through filter paper, filled into a glass bottle, capped and sterilized by heating to prepare a liquid.
[0018]
Comparative Example 2
Licorice soft extract 200 mg (corresponding to licorice 800 mg) was dissolved in purified water, and riboflavin sodium phosphate 5 mg, pyridoxine hydrochloride 30 mg, fructose glucose liquid sugar 10 g, citric acid 150 mg and ethyl parahydroxybenzoate 10 mg were dissolved therein. The aqueous solution was adjusted to pH 4.5, purified water was added to make the total volume 100 ml, filtered through filter paper, filled into a glass bottle, capped and heat sterilized to obtain a liquid.
[0019]
Comparative Example 3
Licorice extract 400 mg (corresponding to 2000 mg of licorice), carrot extract 50 mg (corresponding to carrot 350 mg), and 1 g of goldfish tincture (corresponding to 10 mg of carrot) are dissolved in purified water, and this is dissolved in 1000 mg of aminoethylsulfonic acid, 5 mg of riboflavin sodium phosphate, hydrochloric acid 30 mg of pyridoxine, 10 g of sucrose, 200 mg of citric acid and 10 mg of butyl paraoxybenzoate were added and dissolved. The aqueous solution was adjusted to pH 5.0, purified water was added to make the total volume 100 ml, filtered through filter paper, filled into a glass bottle, capped and sterilized by heating to obtain a liquid.
[0020]
Comparative Example 4
Licorice extract 5000 mg (equivalent to licorice 5000 mg) was dissolved in purified water, and acetaminophen 500 mg, d-chlorpheniramine maleate 2 mg, dihydrocodeine phosphate 10 mg, sodium benzoate caffeine 150 mg, riboflavin sodium phosphate 4 mg 25 mg of pyridoxine hydrochloride, 15 g of sucrose, 150 mg of citric acid and 12 mg of butyl paraoxybenzoate were added and dissolved. The aqueous solution was adjusted to pH 5.0, purified water was added to make the total volume 100 ml, filtered through filter paper, filled into a glass bottle, capped and sterilized by heating to obtain a liquid.
[0021]
<Comparison test>
The liquid preparations of the present invention obtained in Examples 1 to 4 and the liquid preparations obtained in Comparative Examples 1 to 4 were stored under conditions of 40 ° C.-75% relative humidity and 25 ° C., and the appearance of the contents liquid was observed. The degree of appearance deterioration was determined based on the appearance observation criteria shown in Table 1.
[0022]
[Table 1]
Figure 0003864431
[0023]
The test results are shown in Tables 2 and 3.
[0024]
[Table 2]
Figure 0003864431
[0025]
[Table 3]
Figure 0003864431
[0026]
As is apparent from Tables 2 and 3, the liquid agent of the comparative example showed remarkable deterioration in appearance, whereas the liquid agent of the present invention showed almost no deterioration in appearance and had excellent appearance stability. Proved.
[0027]
【The invention's effect】
The liquid preparation of the present invention is extremely useful because it is excellent in appearance stability and hardly deteriorates in appearance such as precipitation, suspension, and suspended matter formation when stored for a long period of time.

Claims (4)

カンゾウの抽出物に、ポリオキシエチレン・ポリオキシプロピレングリコールを配合することを特徴とする液剤A liquid preparation comprising licorice extract mixed with polyoxyethylene / polyoxypropylene glycol カンゾウの抽出物に、ポリオキシエチレン・ポリオキシプロピレングリコール及びポリビニルピロリドンを配合することを特徴とする液剤 A liquid preparation comprising licorice extract blended with polyoxyethylene / polyoxypropylene glycol and polyvinylpyrrolidone カンゾウの抽出物の配合量が原生薬換算量として0.01〜5重量%である請求項第1〜2項に記載の液剤The liquid preparation according to claim 1 or 2, wherein the compounding amount of the extract of licorice is 0.01 to 5% by weight as the amount of the active ingredient. ポリオキシエチレン・ポリオキシプロピレングリコールの配合量が0.01〜2重量%である請求項第1〜3項に記載の液剤The liquid agent according to claims 1 to 3 , wherein the blending amount of polyoxyethylene / polyoxypropylene glycol is 0.01 to 2% by weight.
JP16788195A 1995-06-12 1995-06-12 A stable solution containing licorice extract Expired - Fee Related JP3864431B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP16788195A JP3864431B2 (en) 1995-06-12 1995-06-12 A stable solution containing licorice extract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16788195A JP3864431B2 (en) 1995-06-12 1995-06-12 A stable solution containing licorice extract

Publications (2)

Publication Number Publication Date
JPH08333268A JPH08333268A (en) 1996-12-17
JP3864431B2 true JP3864431B2 (en) 2006-12-27

Family

ID=15857819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16788195A Expired - Fee Related JP3864431B2 (en) 1995-06-12 1995-06-12 A stable solution containing licorice extract

Country Status (1)

Country Link
JP (1) JP3864431B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1249249A1 (en) * 2000-12-12 2002-10-16 Menicon Co., Ltd. Ophthalmic composition
JP4889948B2 (en) * 2005-01-21 2012-03-07 興和株式会社 An oral solution with excellent ingestion
GB0501654D0 (en) * 2005-01-26 2005-03-02 Veritron Ltd Stabilised plant extract
JP5845807B2 (en) * 2011-10-28 2016-01-20 ゼリア新薬工業株式会社 Carbonated internal use liquid
JP6114133B2 (en) * 2013-07-19 2017-04-12 大鵬薬品工業株式会社 Kokushi extract-containing oral solution, solubilizer and solubilization method

Also Published As

Publication number Publication date
JPH08333268A (en) 1996-12-17

Similar Documents

Publication Publication Date Title
JP4445590B2 (en) Oral liquid composition containing paroxetine-resin
AU753478B2 (en) Pharmaceutical formulations
CA2140347C (en) Injection and injection kit containing omeprazole and its analogs
RU2314810C2 (en) Method for treatment using medicinal formulations containing pharmaceutical compositions of 5,8,14,-triazatetracyclo[10.3.1.0 (2,11).0(4,9)]hexadeca-2( 11),3,5,7,9-pentaene
EP2395979B1 (en) Delayed release, oral dosage compositions that contain amorphous cddo-me
CA1312549C (en) Instant oral-release capsule containing nifedipine
JPH0761941B2 (en) Boiling composition with analgesic effect
PT1379222E (en) Orodispersible effervescent tablets
JP2008512363A (en) Methods for enhancing absorption of transmucosal preparations
AU2018420535B2 (en) Edaravone pharmaceutical composition
JP2000212094A (en) Pharmaceutical preparation for oral cavity
KR20170091778A (en) Pharmaceutical pemetrexed solution
MXPA04009735A (en) Low dose liquid entecavir formulations and use.
JP3864431B2 (en) A stable solution containing licorice extract
JPWO2002051411A1 (en) Famotidine injection
EP1603550B1 (en) Pharmaceutical composition comprising 5-methyl-2-2&#39;-(chloro-6&#39;-fluoroanilino)phenylacetic acid
JP6410814B2 (en) Liquid pharmaceutical composition for oral administration containing fexofenadine
WO2011093831A2 (en) Effervescent formulations comprising cefprozil as active agent
JP4403587B2 (en) Herbal extract formulation solution stable at low pH
KR102413426B1 (en) Orally disintegrating film comprising naratriptan
KR100435514B1 (en) Fast dissolving formulation of sildenafil lactate
EP3322402B1 (en) Compositions of midazolam for buccal administration in the treatment of seizures to obtain rapid onset of action
JPH085784B2 (en) Syrup
JPH1135489A (en) Solution preventing decomposition of polyoxyethylene hardened castor oils
JP2000219628A (en) Previously mixed injectable composition of alatrofloxacin

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060606

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060925

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101013

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111013

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121013

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131013

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees